甲基强的松龙治疗在急性期多发性硬化的应用效果

Abstract
Figure/Table
References (15)
Related Citation (0)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical effect and safety of Methylprednisolone in the treatment of acute multiple sclerosis. Methods A total of 94 patients with acute multiple sclerosis admitted to our hospital from January 2018 to August 2019 were selected as the research subjects.They were divided into the reference group (n=47) and the study group (n=47) by the random number table method.Dexamethasone combined with Methylprednisolone treatment was applied in the reference group, 20 mg of Dexamethasone dissolved in 500 ml of 0.9% sodium chloride was injected intravenously for 5 days, followed by oral administration of 10 mg of Methylprednisolone daily for 90 days.In the study group, patients were treated with Methylprednisolone, 1000 mg of Methylprednisolone dissolved in 500 ml of 0.9%sodium chloride was injected intravenously for 5 days, followed by oral administration of 60 mg of Methylprednisolone daily for 90 days.The levels of CD4+, CD8+, CD4+/CD8+ and the total incidence rate of adverse reaction were compared between the two groups. Results There was no significant difference in the level of CD4+ between the two groups after treatment (P＞0.05).The level of CD8+ in the study group after treatment was higher than that of the reference group,and the difference was statistically significant (P＜0.05).There was no significant difference in the level of CD4+/CD8+between the two groups after treatment (P＞0.05).The total incidence rate of adverse reaction in the study group was lower than that of the reference group, and the difference was statistically significant (P＜0.05). Conclusion Methylprednisolone applied in the treatment of acute multiple sclerosis can effectively regulate the balance of T lymphocyte subsets and reduce patients′ adverse reactions, which is worthy of promotion.

Key words： Methylprednisolone Acute phase Multiple Sclerosis Application effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Hong-yan

Cite this article:

GUO Hong-yan. Application effect of Methylprednisolone in the treatment of acute multiple sclerosis[J]. 中国当代医药, 2020, 27(15): 77-79.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I15/77

[1]	段瑞芬，王秉卿，赵浪芳，等.注射用丹参多酚酸对视神经脊髓炎谱系疾病急性期疗效观察及胶质纤维酸性蛋白水平的影响[J].药物评价研究，2019，42（2）：234-239.
[2]	李林溪.甲基强的松龙治疗急性期多发性硬化症的应用效果及神经功能评分影响观察[J].中医临床研究，2019，11（27）：24-25.
[3]	朱明睿.甲基强的松龙治疗急性期多发性硬化症的临床价值研究[J].中国医药指南，2018，16（24）：37-38.
[4]	崔晓，刘启兵，张真.探讨甲基强的松龙治疗急性期多发性硬化的临床效果及安全性[J].中外医学研究，2017，15（19）：11-13.
[5]	梁凤仙.甲基强的松龙治疗急性期多发性硬化症的临床效果[J].当代医学，2019，25（29）：25-27.
[6]	杨仁妹.鞘内注射甲基强的松龙治疗急性期多发性硬化患者的临床效果[J].中国药物经济学，2017，12（5）：82-84.
[7]	孙福霞.甲基强的松龙治疗多发性硬化的应用与疗效探究[J].中国现代药物应用，2017，11（21）：110-111.
[8]	辛琳琳，张卫红，杨红玉，等.甲基强的松龙鞘内注射治疗急性期多发性硬化的疗效观察[J].中国实用医药，2016，11（24）：140-141.
[9]	宋元清，王士列，李年春.甲基强的松龙鞘内注射治疗急性期多发性硬化的临床研究[J].当代医学，2016，22（21）：138-139.
[10]	郑文鑫，杨硕，吴暇.探究甲基强的松龙在复发缓解型多发性硬化患者中的应用[J].中国保健营养，2018，28（20）：30.
[11]	蒋觉安，刘翠平，薛群，等.共刺激分子OX40 和OX40L在多发性硬化患者外周血中的表达[J].中华神经医学杂志，2019，18（4）：375-380.
[12]	王松.观察甲基强的松龙在复发缓解型多发性硬化患者中的应用效果[J].中国实用医药，2017，12（2）：96-98.
[13]	黄琴，谢宁，罗纳川，等.粒细胞集落刺激因子和促红细胞生成素单药或联合用药治疗多发性硬化的临床效果分析[J].中国医科大学学报，2019，48（10）：919-925.
[14]	刘宁.鞘内注射甲基强的松龙用于多发性硬化治疗的效果评价[J].中国保健营养，2018，28（22）：102.
[15]	成鸿毅，奚佳铭，王春梅，等.儿童多发性硬化15 例临床分析[J].精准医学杂志，2018，33（6）：505-507，511.